KUKJEON PHARMACEUTICAL Co.,Ltd
Financials
Valuation Metrics
KUKJEON PHARMACEUTICAL Co.,Ltd's Market Cap is ₩1266B. At end of 2025 it was ₩1817B. Ranked #1134 of 2,421 in KR market (top 47%), #598 of 1,640 on KOSDAQ (top 36%), #129 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 126.60B KRW | KR#1,134/2,421 Sec#129/231 |
| Revenue | 134.57B KRW | KR#1,245/2,421 Sec#77/231 |
| Net Income | -2.08B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 189.20B KRW | KR#1,353/2,421 Sec#98/231 |
| Net Assets | 114.00B KRW | KR#1,323/2,421 Sec#105/231 |
| Employees | 175 | KR#1,191/2,421 Sec#98/231 |
| Value | ||
| P/B | 1.11x | KR#1,556/2,421 Sec#102/231 |
| P/S | 0.94x | KR#1,347/2,421 Sec#80/231 |
| EV/EBITDA | 67.33x | KR#1,421/2,421 Sec#94/231 |
| FCF Yield | 5.92% | KR#793/2,421 Sec#39/231 |
| Profitability | ||
| ROE | -1.83% | KR#1,676/2,421 Sec#116/231 |
| ROA | -1.10% | KR#1,686/2,421 Sec#117/231 |
| Op. Margin | 1.68% | KR#1,425/2,421 Sec#100/231 |
| Revenue Growth | -0.37% | KR#1,552/2,421 Sec#153/231 |
| Financial Health | ||
| Debt Ratio | 65.96% | KR#1,170/2,421 Sec#141/231 |
| Total Debt | 39.89B KRW | KR#1,101/2,421 Sec#77/231 |
| FCF | 7.49B KRW | KR#795/2,421 Sec#48/231 |
| Cash | 14.18B KRW | KR#1,476/2,421 Sec#119/231 |
| Current Ratio | 1.47x | KR#1,231/2,421 Sec#132/231 |
| Net Debt/EBITDA | 11.36x | KR#1,262/2,421 Sec#91/231 |
| Dividend | ||
| Div. Yield | 0.78% | KR#1,178/2,421 Sec#73/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -41.96% | KR#1,884/2,421 Sec#161/231 |
| 1M Return | 9.32% | KR#513/2,421 Sec#35/231 |
| From 52W High | -60.92% | KR#1,890/2,421 Sec#149/231 |
| 1Y MDD | -67.51% | KR#1,863/2,421 Sec#158/231 |
| Trading | ||
| Volume | 145,616 shares | KR#607/2,421 Sec#50/231 |
| Trading Value | 341.4M KRW | KR#1,080/2,421 Sec#109/231 |
| Foreign Own. | 1.25% | KR#1,936/2,421 Sec#188/231 |
| Per Share | ||
| EPS | -39 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,112 KRW | KR#2,045/2,421 Sec#169/231 |
Company Info
Kukjun Pharm, established in 1995 and listed on KOSDAQ in 2020, is a chemical total solution company. Utilizing chemical synthesis technology, it produces active pharmaceutical ingredients (APIs), OLED materials, semiconductor materials, and secondary battery electrolyte additives, operating in both pharmaceutical and material business sectors. The company is conducting Phase 1 clinical trials for an Alzheimer's treatment with Shaperon and Phase 3 clinical trials for a combination treatment with TH Pharm, and constructed a factory in Eumseong-gun in 2023 for the commercial production of materials for AI semiconductor processes. Kukjun Pharm is headquartered in Anyang-si, Gyeonggi-do.